Climb Bio, Inc. (CLYM) – What Are Researchers Saying About This Stock?

Shares of Climb Bio, Inc. (NASDAQ:CLYM) have earned a consensus rating of “Buy” from the fourteen analysts that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, eleven have given a buy rating and two have issued a strong buy rating on the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $27.62.

CLYM has been the subject of a number of analyst reports. Wedbush reaffirmed an “outperform” rating and set a $20.00 price objective on shares of Climb Bio in a report on Wednesday, August 19th. Royal Bank Of Canada initiated coverage on shares of Climb Bio in a research note on Monday, August 3rd. They issued an “outperform” rating and a $23.00 target price on the stock. Raymond James Financial reissued a “strong-buy” rating and issued a $34.00 target price on shares of Climb Bio in a research note on Monday, October 5th. Piper Sandler set a $40.00 price target on shares of Climb Bio and gave the stock an “overweight” rating in a research report on Thursday, September 3rd. Finally, Truist Financial raised their price target on shares of Climb Bio from $17.00 to $25.00 and gave the stock a “buy” rating in a research note on Friday, August 7th.

Insider Buying and Selling at Climb Bio

In other news, Director Stephen Thomas sold 100,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $13.67, for a total value of $1,367,000.00. Following the sale, the director directly owned 467,969 shares in the company, valued at approximately $6,397,136.23. This represents a 17.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 2.60% of the company’s stock.

Hedge Funds Weigh In On Climb Bio

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Legal & General Group Plc bought a new stake in Climb Bio in the second quarter valued at $45,000. Spark Investment Management LLC bought a new position in shares of Climb Bio during the second quarter valued at $177,000. State of Wyoming bought a new position in shares of Climb Bio during the second quarter valued at $187,000. Bank of America Corp DE acquired a new stake in shares of Climb Bio in the 2nd quarter valued at $335,000. Finally, Deutsche Bank AG acquired a new stake in shares of Climb Bio in the 2nd quarter valued at $452,000. Institutional investors own 69.76% of the company’s stock.

Climb Bio Price Performance

Shares of CLYM stock opened at $9.82 on Wednesday. Climb Bio has a one year low of $1.63 and a one year high of $18.33. The stock has a fifty day moving average price of $13.73 and a 200 day moving average price of $12.02. The stock has a market cap of $564.06 million, a P/E ratio of -11.83 and a beta of -0.04.

Climb Bio (NASDAQ:CLYM) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.03. Equities research analysts anticipate that Climb Bio will post -0.78 EPS for the current year.

Climb Bio Company Profile

Climb Bio, Inc is a clinical-stage biotechnology company focused on developing novel therapies for patients with immune-mediated diseases, including autoimmune disorders. The company’s research is centered on addressing underlying drivers of abnormal immune activity and developing treatments intended to provide durable disease control.

Climb Bio’s activities include the discovery, development and clinical evaluation of investigational biologic medicines. Its programs are designed to target pathways involved in B-cell function, autoantibody production and other mechanisms that contribute to autoimmune disease.